tbuckley/cabot-search huggingface dataset:
Abstract MP027: Systolic Blood Pressure Reduction with Diet and Exercise is Attenuated in Diabetes
Authors: Devon A Dobrosielski, Rajat Dhungana, Dipan Desai, Harry A Silber, Sammy Zakaria, Edward P Shapiro, Pamela Ouyang, Kerry J Stewart
Journal: Circulation (2012)

Background: Type 2 diabetes (T2DM) and prediabetes (preDM) are insulin resistant conditions associated with being overweight or obese. Increased BP and excessive abdominal fat further increase the risk of cardiovascular disease in these conditions. Exercise reduces BP and abdominal fat independent of weight loss. We hypothesized that a weight loss diet plus supervised exercise training will produce greater reductions in BP and abdominal fat than diet alone in individuals with T2DM and preDM. Methods: This prospective clinical trial randomized persons aged 35–65 yrs with T2DM or preDM to 6-months of either an American Diabetes Association weight loss diet (D); or D combined with supervised moderate-intensity aerobic and resistance exercise training 3 times per week (D+E). Diabetes was defined as having fasting glucose ≥ 126 mg/dl or currently on oral hypoglycemic medication. Prediabetes was defined as having fasting glucose between 100 and 125 mg/dL. Results: Fifty five participants (55.9 ± 7.3 years; 27 T2DM, 28 preDM) completed the study (24 D; 31 D+E). At baseline, there were no group differences in the following, and the combined values (mean ± SD) are: body weight (96.8 ± 16.1 kg), BP (126.7 ± 14.3 / 73.0 ± 8.4 mmHg) and total abdominal fat (711.9 ± 143.5 g) as measured by magnetic resonance imaging. At 6 months, reductions from baseline were observed in both groups for body weight (D: −6.1 ± 3.7 %; D+E: −6.9 ± 4.1 %), BP (D:−7.7 ± 13.1 / −5.7 ± 7.1 mmHg; D+E: −8.8 ± 17.1 / −4.6 ± 9.2 mmHg) and abdominal fat (D: −102.0 ± 68.6 g; D+E: ± −98.7 ± 72.7 g) (all p-values &lt; 0.01 for change from baseline ). No differences in the change from baseline for these outcomes were observed between groups. Across the entire cohort, participants with T2DM versus preDM had an attenuated reduction in SBP (−4.1 ± 11.4 mmHg vs. −12.3 ± 17.7 mmHg p&lt;0.05), whereas achieved weight loss or abdominal fat loss did not differ by diabetes status. Change in SBP did not correlate with the change in body weight (r=0.04, p=0.79) or abdominal fat (r=0.06, p=0.73). Conclusions: Contrary to our hypothesis, adding exercise to diet did not further reduce SBP or abdominal fat. A novel finding that emerged from these data is that despite similar weight loss with both programs, the mean reduction in SBP was approximately 7 mmHg less in T2DM compared to those with preDM. These data suggest that the factors responsible for improved BP with diet and exercise extend beyond total body weight lost or changes in central obesity, and that these factors may be modified with T2DM.
Does Rituximab Influence the Prognostic Effect of Germinal Centre Phenotype in Diffuse Large B-Cell Lymphoma?.
Authors: Heidi Nyman, Marja-Liisa Karjalainen-Lindsberg, Minna Taskinen, Mattias Berglund, Magdalena Adde, Rose-Marie Amini, Carl Blomqvist, Gunilla Enblad, Sirpa Leppä
Journal: Blood (2006)
Micro-RNA Expression Profile Reveals MiR-222 As a Potential Biomarker For EBV-Positive Diffuse Large B-Cell Lymphoma
Authors: Tathiana Azevedo de Andrade, Adriane Feijo Evangelista, Natalia Morais Borges, Antonio Hugo Froes Campos, Claudia Camillo, Fernando A Soares, Jose Vassallo, Roberto Pinto Paes, Maria Claudia Zerbini, Cristovam Scapulatempo, Antonio Correa Alves, Gisele Wally Braga Colleoni
Journal: Blood (2013)
Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.
Authors: Marcello Rotta, Barry Storer, Firoozeh Sahebi, Judith A. Shizuru, Benedetto Bruno, Thoralf Lange, Peter A. McSweeney, Michael Pulsipher, Parameswaran Hari, Richard Thomas Maziarz, Edward Agura, Thomas Chauncey, Frederick Appelbaum, William Bensinger, Brenda Sandmaier, Rainer Storb, David G. Maloney
Journal: Blood (2008)
TCT-668 Transcatheter aortic valve implantation in degenerated aortic bioprosthesis: an analysis from the Brazilian TAVI Registry
Authors: Guilherme Bernardi, Fernando L. de Melo Bernardi, Paulo R. Prates, Pedro A. Lemos, Dimytri A. Siqueira, Jose A. Mangione, Adriano Dourado, Luiz Antonio Carvalho, Luiz Eduardo São Thiago, Valter Lima, Júlio Andrea, Fábio Brito, Rogério Rogério Sarmento-Leite
Journal: Journal of the American College of Cardiology (2015)
TCT-607 Neointimal Transformation and Late Stent Failure from 2 months to 2 years of the New Dual Therapy Endothelial Progenitor Cell Capturing Sirolimus-eluting COMBO Stent by Longitudinal Sequential OCT: The EGO-COMBO Study
Authors: Stephen W. Lee, Akiko Maehara, Kelvin Ki Wan Chan, Shun Ling Kong, Simon CC. Lam, Chor Cheung Frankie Tam, Michael Ka Lam Wong, Anthony Yiu Tung Wong, Arthur See Yue Yung, Catherine P. Shea, Michael Haude, Roxana Mehran, Gary S. Mintz
Journal: Journal of the American College of Cardiology (2015)
Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches
Authors: Antonella Antonelli, Willy A. Noort, Jenny Jaques, Bauke de Boer, Regina de Jong-Korlaar, Annet Z. Brouwers-Vos, Linda Lubbers-Aalders, Jeroen F. van Velzen, Andries C. Bloem, Huipin Yuan, Joost D. de Bruijn, Gert J. Ossenkoppele, Anton C. M. Martens, Edo Vellenga, Richard W. J. Groen, Jan Jacob Schuringa
Journal: Blood (2016)
A Continous Recurrent Course in a Case of Nodular-Sclerosis (NS) Classical Hodgkin’s Lymphoma (cHL) Associated with Castleman’s Disease (CD).
Authors: Annamaria Rauco, Fabrizio Liberati, Rosanna Capozzi, Maria G. Morandi, Roberta Pace, Vincenzo Capparella, Michele Cianciulli, Anna M. Liberati
Journal: Blood (2005)
Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor
Authors: Wael Harb, Mansoor N. Saleh, Kyriakos P Papadopoulos, Feng Chai, Maria Larmar, Giovanni Abbadessa, Brian Schwartz, Anthony Tolcher
Journal: Blood (2015)
Efficacy and safety of cetuximab (C) given with a simplified, every other week (q2w), schedule in patients (pts) with advanced colorectal cancer (aCRC): A multicenter, retrospective study
Authors: M. Bouchahda, T. Macarulla, G. LIedo, F. Lévi, M. E. Elez, A. Karaboué, P. Artru, J. Tabernero, V. Castagne, R. Gimbaud
Journal: Journal of Clinical Oncology (2008)

15118 Background: Efficacy and safety of C have been validated with the regulatory approved a weekly schedule in combination with chemotherapy (CT). Most CT regimens used in aCRC are given on a q2w basis. A pharmacokinetic/pharmacodynamic phase I study (Tabernero J, et al. JCO 2006, 24: 142s (Abstract 3085)) and a clinical study (Pfeiffer P, et al. JCO 2007, 25:196s (Abstract 4133) have suggested that a q2wks schedule (500 mg/m2) is equivalent to the standard weekly administration (400 mg/m2 loading dose, then 250 mg/m2). Thus, in clinical practice C is frequently used with a simplified q2w schedule. We have assessed the efficacy (response rate [RR], time to progression [TTP] and overall surival [OS] and safety of C administered q2w in pts with aCRC treated in 4 academic centers. Methods: Based on pharmacy registries, all patients (pts) with aCRC who received C q2w were retrospectively reviewed. Data were collected from medical records on specific CRFs, checked for consistency by an independent monitor. Descriptive analysis was performed. Results: Ninety-one pts were treated (44F/47M; median age 61 [32–83]; PS 0/1/2 in 33/50/17%; EGFR positive 31%, negative13%, unknown 56%; median metastatic sites 2 [0–5]. Pts had previously received a median of 3 (0–8) lines of CT and 4 (0–7) drugs, including previous weekly C in 37%. C q2w was given with various CT regimens, mainly with irinotecan alone (40%) or FOLFIRI (40%). Bevacizumab was concomitantly given in 11% pts. The median number of C cycles was 5 (1–23). RR was 26% of treated and 32% of evaluable pts. Median TTP was 4.8 months (0.5–15.9) and median OS was not reached (range: 1.0–21.5 months). Skin toxicity was observed in 59 out of 85 (69%) evaluable pts (grade 1–2 in 46 and 3 in 13). RR in pts with and without rash was 37% and 4% respectively. No grade ¾ hypersensitivity events were reported. Conclusions: C administered q2w appears safe and effective, even in heavily pretreated pts and it is more convenient in combination with q2wCT schedules. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Merck Serono
Murine Hemophilia A With Or Without Pre-Existing Anti-Factor VIII Inhibitors Is Partially Corrected By Factor VIII Stored In Platelets After Intraosseous Infusion Of Lentiviral Vectors Into Bone Marrow Without Preconditioning
Authors: Xuefeng Wang, Simon C. Shin, Chiang Andy, Dao Pan, David Rawlings, Carol H. Miao
Journal: Blood (2013)
GW27-e0270 A study on the mechanism of the inflammatory response in Ginsenoside Rb1 against the intrinsic aging of mouse brain
Authors: Bin Zhou, Shujie Yu, Yong Liu, Dinghui Liu, Lin Wu, Min Wang, Xianguan Yu, Baoshun Hao, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2016)
Targeted Protein Degradation by Small Molecules
Authors: Daniel P. Bondeson, Craig M. Crews
Journal: The Annual Review of Pharmacology and Toxicology (2016)

Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of disease-relevant proteins. Here, we review recent advances in the use of small molecules to degrade proteins in a selective manner. First, we highlight all-small-molecule techniques with direct clinical application. Second, we describe techniques that may find broader acceptance in the biomedical research community that require little or no synthetic chemistry. In addition to serving as innovative research tools, these new approaches to control intracellular protein levels offer the potential to develop novel therapeutics targeting proteins that are not currently pharmaceutically vulnerable.
Whole Transcriptome Sequencing Identifies Novel Pathways Associated with Paroxysmal Nocturnal Hemoglobinuria- Increased CXCR2 Expression in PNH Granulocytes
Authors: Kohei Hosokawa, Sachiko Kajigaya, Keyvan Keyvanfar, Danielle M. Townsley, Bogdan Dumitriu, Marie Desierto, Olga Rios, Barbara Weinstein, Xingmin Feng, Neal S. Young
Journal: Blood (2015)
Operationalizing and Examining Family Planning Vigilance in Adult Women With Type 1 Diabetes
Authors: Susan M. Sereika, Dorothy Becker, Patricia Schmitt, A. Blair Powell, Ana Maria Diaz, Andrea F.R. Fischl, Jennifer Thurheimer-Cacciotti, William H. Herman, Denise Charron-Prochownik
Journal: Diabetes Care (2016)

OBJECTIVE Because unplanned pregnancies could cause maternal-fetal complications for women with diabetes, family planning vigilance (FPV) is imperative. The aims of this article are to operationalize and describe FPV and examine the associations among FPV behaviors and diabetes self-care management (DSM) and health outcomes of women with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS Retrospective data were used from a follow-up study of adult women with T1D who participated as adolescents in a preconception counseling (PC) intervention trial and matched comparison women with T1D who did not receive the adolescent PC intervention. Participants completed online questionnaires regarding family planning behaviors, DSM, and clinical and reproductive health outcomes. RESULTS Participants (N = 102) were, on average, 23.7 years old (range 18–38) and 98.0% were white, 82.2% had some college, 25.8% were married, and 11.8% had biological children. Of those sexually active (n = 80, 78.4%), 50% were contraceptive vigilant and 11% were FPV (i.e., being contraceptive vigilant, receiving PC, and initiating discussions with health care professionals). Among FPV behaviors, only receiving PC and initiating discussion with health care professionals were correlated (r = 0.29, P = 0.010). Compared with nonvigilant women, contraceptive vigilant and FPV women used more effective contraceptive methods (P = 0.025) and experienced less diabetic ketoacidosis (P = 0.040) and hospitalizations (P = 0.064), whereas FPV women were aware of PC (P = 0.046) and younger when they received PC (P &amp;lt; 0.001). FPV components were associated with DSM and health outcomes (P &amp;lt; 0.05). CONCLUSIONS Women with diabetes should be FPV, but few were. FPV women were more likely to have PC earlier and better health outcomes, supporting early PC intervention.
Targeting the Hypoxic Microenvironment by mTOR Inhibitors Sensitizes ALL Cells to Chemotherapy
Authors: Olga Frolova, Ismael J. Samudio, Zakar H. Mnjoyan, Hongbo Lu, Sergej Konoplev, Deborah A. Thomas, Hagop M. Kantarjian, Elizabeth J. Shpall, Michael Andreeff, Marina Konopleva
Journal: Blood (2008)
Vitamin E in the neuroprotection of cisplatin induced peripheral neurotoxicity and ototoxicity
Authors: A. Pace, S. Carpano, E. Galiè, A. Savarese, M. Della Giulia, A. Aschelter, A. Silvani, L. Di Lauro, B. Jandolo, F. Cognetti
Journal: Journal of Clinical Oncology (2007)

9114 Background: Peripheral neurotoxicity is a well recognized effect of cisplatin chemotherapy that can result in severe disability and represents a major dose-limiting factor. Several phase II studies have recently investigated the role of vitamin E as neuroprotectant in the prevention of cisplatin induced peripheral neurotoxicity and ototoxicity. Methods: An Italian randomized, placebo controlled, double blind multicentric study is ongoing to confirm the role of vitamin E supplementation in the prevention of neurotoxicity and ototoxicity induced by cisplatin Patients candidates to cisplatin chemotherapy were randomised to either vitamin E supplementation (a-tocopherol 400 mg/day) or to placebo. Patients were evaluated with neurological and neurophysiological examination before and after treatment. Neurotoxicity was measured using the comprehensive clinical and neurophysiological Total Neuropathy Score (TNS). Ototoxicity was evaluated with audiometric test and acoustic evoked potential before and after treatment. Results: 81 patients have been enrolled in 3 italian oncologic centers. An interim analysis on the first 50 patients was carried out. 25 patients (11 in the vit E group and 14 in the placebo group) received a cumulative dose higher than 300 mg/mq and were evaluable for neurotoxicity. Statistical analysis showed a significant difference (p &lt; 0.05) in median neurotoxicity score observed in vit E group (TNS=1) respect to the placebo group (TNS=5). Conclusions: This is the first randomised, placebo controlled, double blind trial exploring the efficacy of vitamin E in the neuroprotection of cisplatin neurotoxicity. The results of this study confirm the neuroprotective effect of vitamin E supplementation against cisplatin-induced neurotoxicity. No significant financial relationships to disclose.
TCT-690 Prognostic Value of Body Surface Area on Clinical Outcomes after Transcatheter Aortic Valve Replacement
Authors: Mani Arsalan, John J. Squiers, Giovanni Filardo, Won-Keun Kim, Benjamin D. Pollock, Johannes Blumenstein, Christoph Liebetrau, Arnaud Van Linden, Helge Moellmann, Thomas Walther
Journal: Journal of the American College of Cardiology (2015)
DNA Methylation Profiling of Sorted Peripheral Blood Cells Using Microarray and Next Generation Sequencing Reveals Distinct Molecular Signatures in the Polymorphonuclear and Mononuclear Cells of Patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis
Authors: Chieh Lee Wong, Baoshan Ma, Martyna Adamowicz-Brice, Gareth Gerrard, Zainul Abidin Norziha, Nor Rafeah Tumian, Soon Keng Cheong, Chooi Fun Leong, Ping Chong Bee, Gin Gin Gan, Jameela Sathar, Letizia Foroni, Tim Aitman, Liming Liang, Michael Laffan
Journal: Blood (2015)
Patients aged 70 or older (≥ 70) with advanced oesophagogastric cancer (OGC) experience similar benefits from palliative chemotherapy compared to younger patients
Authors: M. J. Trumper, A. R. Norman, P. J. Ross, D. Cunningham, R. Hawkins, M. Seymour, P. Harper, T. Iveson, M. Nicholson, T. Hickish
Journal: Journal of Clinical Oncology (2004)

4018 Background: The benefits of chemotherapy for advanced OGC are well established, although there are few data specifically examining such treatment in the elderly. Methods: Between 1992 and 2001, 1080 patients were enrolled into 3 randomised trials of chemotherapy; 702 received a cisplatin-containing regimen, 126 FAMTX and 252 5-fluorouracil +/- mitomycin C (5-FU +/- MMC). Treatment was for 24 weeks with CT scan assessment at 12 and 24 weeks. This analysis compares the outcome between patients aged ≥ 70 years with those <70 years. Results: 257 patients were ≥ 70. Baseline characteristics were well balanced except there were more patients <70 with metastatic disease (76.5% v 62.4% p<0.001). There were no significant differences in grades 3/4 haematological and non-haematological toxicities. After adjusting for chemotherapy regimens no significant differences were identified in response rates between the age groups and were 43% v 44% with platinum-containing regimens (p=0.9), 6% v 21% with FAMTX (p=0.3) and 17% v 18% in the 5-FU +/- MMC group. Symptom improvement rates for dysphagia, reflux, pain, anorexia, nausea and vomiting were not significantly different between the age groups and ranged from 59–80%. 1-year survival in patients ≥ 70 and < 70 with cisplatin-containing regimens was 35.3% v 35.2%, 6.7% v 23.4% with FAMTX and 20.8% v 20 % with 5-FU +/- MMC. On multivariate analysis controlling for PS, locally advanced disease and treatment, there was no significant difference in overall survival (p=0.46) and failure free survival (p=0.94) by age. Conclusion: Patients ≥ 70 years with OGC obtain the same benefit from palliative chemotherapy with respect to symptomatic response, tumour regression and survival, without increased toxicities. No significant financial relationships to disclose.
High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes
Authors: Yinlei Bai, Kwan Yeung Wong, Tsz Kin Fung, Chor Sang Chim
Journal: Journal of Hematology & Oncology (2016)

Allele-specific oligonucleotide real-time quantitative PCR (ASO-RQPCR) is a standardized technique for detection and monitoring of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) but not multiple myeloma (MM) due to a low applicability inherent with presence of somatic hypermutation. Herein, by a staged PCR approach and sequencing, clonality and tumor-specific complementarity-determining region 3 (CDR3) sequence were identified in 13/13 MM by sequential PCR of IgH VDJ (n = 10), IgH DJ (n = 2), or IgK VJ (n = 1). Using consensus primers/probes conventionally employed in ALL, ASO-RQPCR worked in three (23.1 %) cases only. Conversely, using entirely patient-specific primers/probes, ASO-RQPCR was applicable in eight (61.5 %) cases with a sensitivity of 5 × 10−4–10−5. Moreover, using standard curves constructed by serial dilution of plasmids cloned with patient-specific CDR3, ASO-RQPCR was successful in 12 (92.3 %) cases with a sensitivity of 10−4–10−5, but not in a case lacking an N region, in which design of a tumor-specific ASO primer was precluded. Finally, in a patient in complete response (CR), further reduction of MRD after autologous stem cell transplantation (ASCT) was demonstrated. In summary, using entirely patient-specific primers/probes, ASO-RQPCR was applicable in >90 % MM patients and enabled detection of dynamic changes of MRD before and after ASCT despite conventional CR.
Dose Dependent Role of Gfi1 in Human MDS and AML and Its Suitability As a Novel Target
Authors: Judith Maria Hönes, Lacramioara Botezatu, Lars C. Michel, Christian Thiede, Bert van der Reijden, Michael Heuser, Hideki Makishima, Jaroslaw P. Maciejewski, Tomas Radiovoyevitch, Gerhard Ehninger, Ulrich Dührsen, Tarik Moroy, Cyrus Khandanpour
Journal: Blood (2014)
Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia
Authors: Adam Lamble, Yoko Kosaka, Pierrette Lo, Fei Huang, Kate Sasser, Cristina E. Tognon, Marc Loriaux, Jeffrey W. Tyner, Brian J. Druker, Evan F. Lind
Journal: Blood (2015)
GW27-e0349 Biodegradable-polymer drug-eluting stents Versus bare metal stents Versus durable-polymer drug-eluting stents in Patients With in Patients Undergoing Coronary Revascularization: a Meta-Analysis of Randomized Controlled Trials
Authors: Zhu Jianbing, Junbo Ge
Journal: Journal of the American College of Cardiology (2016)
Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)
Authors: Kirit M Ardeshna, Peter Hoskin, Paul Smith, Nicholas Chadwick, Nivette Braganca, Wai-Lup Wong, Irfan Kayani, Bal Sanghera, Patricia Diez, Helen Lucraft, Andrew Jack, Christopher J McNamara, George Mikhaeel, Scott Marshall, Ruth Pettengell, Robert E. Marcus, Anton Kruger, David C Linch
Journal: Blood (2012)
Pilot Study of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis.
Authors: Nicolaus Kroeger, Tatjana Zabelina, Heike Schieder, Jens Panse, Francis Ayuk, Natalja Fehse, Boris Fehse, Olga Waschke, Hans M. Kvasnicka, Jurgen Thiele, Axel Zander
Journal: Blood (2004)